Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.

BMC Cancer · 2023 · PMC9985926 · PMID 36872337

Europe PMC DOI

hedged sentence

0.0890

closest p · 1.8× alpha

0.0890

boldest claim

The sentences

did not reach statistical significanceP = 0.089so close (0.05 < p ≤ 0.1)

The results showed that liver metastasis was an independent prognostic factor for PFS (HR: 0.208, 95% CI, 0.044–0.988, P = 0.048), whereas the Lauren classification did not reach statistical significance (HR: 0.322, 95% CI, 0.087–1.188, P = 0.089).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.